InspireMD (NSPR)
(Delayed Data from NSDQ)
$2.66 USD
+0.02 (0.76%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $2.61 -0.05 (-1.88%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.66 USD
+0.02 (0.76%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $2.61 -0.05 (-1.88%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Zacks News
Shockwave Medical (SWAV) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 38.46% and 5.66%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS
by Zacks Equity Research
InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.
Down -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a Turnaround
by Zacks Equity Research
InspireMD, Inc. (NSPR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.29% and 5.31%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights include: Civeo, InspireMD, Westport Fuel Systems, Genesco and Radware
by Zacks Equity Research
Zacks.com featured highlights include: Civeo, InspireMD, Westport Fuel Systems, Genesco and Radware
5 Stocks With Rising P/E That Won't Let You Down
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
InspireMD (NSPR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
InspireMD (NSPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.